Table 3

Showing postoperative complications stratified for randomisation allocation

ComplicationTreatment groupP value
No bevacizumabbevacizumab
Early postoperative period (within 1 month)
 Central retinal vein occlusion1 (1.8%)0 (0.0%) NA
 Hypotonous maculopathy2 (3.6%)2 (3.8%)0.91
 Choroidal effusion1 (1.8%)3 (5.8%)0.27
 Hyphema2 (3.6%)1 (1.9%)0.58
 Wound leak1 (1.8%)2 (3.8%)0.47
Late postoperative period (from 1 month to 12 months)
 Blebitis/endophthalmitis1 (1.8%)0 (0.0%) NA
 Tenon’s cyst1 (1.8%)5 (9.6%)0.08
 Microbial keratitis1 (1.8%)1 (1.9%)0.89
 Corneal endothelial failure1 (1.8%)0 (0.0%) NA
 Hypotonous maculopathy2 (3.6%)3 (5.8%)0.66
  • Although no vision threatening complications were observed within the bevacizumab group, one central retinal vein obstruction and one blebitis/endophthalmitis occurred in the control group. There were no differences in any non-vision-threatening complications between groups (table 3).